|
Jul 31
|
KIT Inhibitors Market Growth: Key Trends and Future Projections in the 7MM Upto 2034 | DelveInsight
|
|
Jul 28
|
Vascarta Announces Addition of Dr. Janet Loesberg to Leadership Team
|
|
Jul 21
|
Sanofi (SNY) Expands Rare Disease Reach With $9.5B Blueprint Deal
|
|
Jul 21
|
Sanofi concludes Blueprint Medicines acquisition
|
|
Jul 18
|
Press Release: Sanofi completes acquisition of Blueprint Medicines
|
|
Jul 17
|
Press Release: Sanofi announces extension of Blueprint tender offer
|
|
Jul 14
|
High Growth Tech Stocks To Watch In The US July 2025
|
|
Jul 14
|
Biotech Stocks Are Ready to Rebound. Gilead Sciences and 2 More to Watch Now.
|
|
Jun 25
|
Exploring US High Growth Tech Stocks For Potential Opportunities
|
|
Jun 24
|
Blueprint Medicines Presents Strong Long-Term Data for AYVAKIT in Systemic Mastocytosis
|
|
Jun 23
|
Exploring 3 High Growth Tech Stocks In The US Market
|
|
Jun 20
|
Exploring 3 High Growth Tech Stocks in the US Market
|
|
Jun 19
|
Exploring Three High Growth Tech Stocks In The US Market
|
|
Jun 17
|
Exploring High Growth Tech Opportunities in US Markets
|
|
Jun 12
|
Blueprint Medicines Announces Data Reinforcing Sustained Clinical Efficacy and Well-Tolerated Safety Profile of Long-Term AYVAKIT®/AYVAKYT® (avapritinib) Treatment at 2025 EHA and EAACI Congresses
|
|
Jun 3
|
Why Blueprint Medicines Corporation (BPMC) Skyrocketed On Monday
|
|
Jun 2
|
These Stocks Are Moving the Most Today: Cleveland-Cliffs, Tesla, GM, Blueprint Medicines, BioNTech, DraftKings, and More
|
|
Jun 2
|
Sanofi Just Spent $9.5 Billion on a Rare Disease You've Never Heard Of
|
|
Jun 2
|
Sanofi Signs a $9.5B Agreement to Acquire Blueprint Medicines
|
|
Jun 2
|
M&A is 'lifeblood' of biopharma: Analyst on Sanofi-Blueprint deal
|